Striking findings in early study of T cell combination therapy – The Pharma Letter (registration)
Endpoints News |
Striking findings in early study of T cell combination therapy
The Pharma Letter (registration) CTL119 is a humanized T cell (CAR–T) cell therapy. T cells are a subtype of white blood cells that are key to the body's natural immune system. Participants in the trial were required to have been taking ibrutinib for at least six months and to not be … Novartis isn't messing around with CAR-T, and it has a promising … Personalized cell therapy combination achieves complete remission in CLL patients |
